These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 26114729)
41. Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report. Na HR; Kim S; Choi SH; Yang DW; Bae HJ; Kim JE; Park MY; Shim YS; Kim BK; Kwon JC; Yoo BG; Kim BC; Lee JS Geriatr Gerontol Int; 2011 Jan; 11(1):90-7. PubMed ID: 20825496 [TBL] [Abstract][Full Text] [Related]
42. Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice. Umegaki H; Itoh A; Suzuki Y; Nabeshima T Int Psychogeriatr; 2008 Aug; 20(4):800-6. PubMed ID: 18341753 [TBL] [Abstract][Full Text] [Related]
43. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting. Wattmo C; Hansson O; Wallin AK; Londos E; Minthon L Dement Geriatr Cogn Disord; 2008; 26(3):203-11. PubMed ID: 18769065 [TBL] [Abstract][Full Text] [Related]
44. Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil. Hatoum HT; Thomas SK; Lin SJ; Lane R; Bullock R J Med Econ; 2009 Jun; 12(2):98-103. PubMed ID: 19492974 [TBL] [Abstract][Full Text] [Related]
45. Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety. Rocca P; Cocuzza E; Marchiaro L; Bogetto F Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):369-73. PubMed ID: 11817515 [TBL] [Abstract][Full Text] [Related]
46. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700 [TBL] [Abstract][Full Text] [Related]
47. Donepezil: a clinical review of current and emerging indications. Román GC; Rogers SJ Expert Opin Pharmacother; 2004 Jan; 5(1):161-80. PubMed ID: 14680445 [TBL] [Abstract][Full Text] [Related]
48. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Aguglia E; Onor ML; Saina M; Maso E Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474 [TBL] [Abstract][Full Text] [Related]
49. Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies. Manabe Y; Ino T; Yamanaka K; Kosaka K Psychogeriatrics; 2016 May; 16(3):202-8. PubMed ID: 26179411 [TBL] [Abstract][Full Text] [Related]
50. Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease. Chase TN; Farlow MR; Clarence-Smith K Neurotherapeutics; 2017 Apr; 14(2):405-416. PubMed ID: 28138837 [TBL] [Abstract][Full Text] [Related]
51. Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease. Yoshida T; Ha-Kawa S; Yoshimura M; Nobuhara K; Kinoshita T; Sawada S Ann Nucl Med; 2007 Jul; 21(5):257-65. PubMed ID: 17634843 [TBL] [Abstract][Full Text] [Related]
52. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Raschetti R; Maggini M; Sorrentino GC; Martini N; Caffari B; Vanacore N Eur J Clin Pharmacol; 2005 Jul; 61(5-6):361-8. PubMed ID: 15912389 [TBL] [Abstract][Full Text] [Related]
53. Efficacy of a high dosage of donepezil for Alzheimer's disease as examined by single-photon emission computed tomography imaging. Kanaya K; Abe S; Sakai M; Fujii H; Koizumi K; Iwamoto T Psychogeriatrics; 2012 Sep; 12(3):172-8. PubMed ID: 22994615 [TBL] [Abstract][Full Text] [Related]
54. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. Weiner MF; Martin-Cook K; Foster BM; Saine K; Fontaine CS; Svetlik DA J Clin Psychiatry; 2000 Jul; 61(7):487-92. PubMed ID: 10937606 [TBL] [Abstract][Full Text] [Related]
55. Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil. Chapman SB; Weiner MF; Rackley A; Hynan LS; Zientz J J Speech Lang Hear Res; 2004 Oct; 47(5):1149-63. PubMed ID: 15603468 [TBL] [Abstract][Full Text] [Related]
56. Comparison of functional and cognitive donepezil effects in Alzheimer's disease. Saine K; Cullum CM; Martin-Cook K; Hynan L; Svetlik DA; Weiner MF Int Psychogeriatr; 2002 Jun; 14(2):181-5. PubMed ID: 12243208 [TBL] [Abstract][Full Text] [Related]
57. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort. Wattmo C; Wallin AK; Minthon L BMC Neurol; 2012 Nov; 12():134. PubMed ID: 23126532 [TBL] [Abstract][Full Text] [Related]
58. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Mohs RC; Doody RS; Morris JC; Ieni JR; Rogers SL; Perdomo CA; Pratt RD; Neurology; 2001 Aug; 57(3):481-8. PubMed ID: 11502917 [TBL] [Abstract][Full Text] [Related]
59. Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer's patients in long-term care health facilities. Meguro K; Ouchi Y; Akanuma K; Meguro M; Kasai M BMC Neurol; 2014 Dec; 14():243. PubMed ID: 25516360 [TBL] [Abstract][Full Text] [Related]